1-8 of 8
James B. Breitmeyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development and Testing of a Glycoengineered Anti-ROR1 Antibody with Enhanced Capacity for Directing Antibody-Dependent Cellular Cytotoxicity (ADCC) of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, George Widhopf II, Christopher Oh, Christina Girgis, Charles E. Prussak, James B. Breitmeyer, Thomas J. Kipps
Journal: Blood
Blood (2023) 142 (Supplement 1): 6836.
https://doi.org/10.1182/blood-2023-187559
Published: 2023
Journal Articles

Trial-in-Progress: A Phase 1/2 Multi-Center Study of Onct-808, a ROR1-Specific CAR T, in Adult Patients with Relapsed/Refractory Aggressive B Cell Lymphoma

Michael L. Wang, Matthew J. Frigault, Salim Yazji, Yisrael Katz, James Robinson, James B. Breitmeyer, Matthew G. Mei, Caron A Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4857.
https://doi.org/10.1182/blood-2023-180989
Published: 2023
Journal Articles

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Hun Ju Lee, Michael Y. Choi, Tanya Siddiqi, Joanna M. Rhodes, William G. Wierda, Iris Isufi, Joseph M Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Michael Wang, Catriona Jamieson, Thomas J. Kipps
Journal: Blood
Blood (2022) 140 (Supplement 1): 566–568.
https://doi.org/10.1182/blood-2022-167153
Published: 2022
Journal Articles

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Hun Ju Lee, Michael Choi, Tanya Siddiqi, Jacqueline Barrientos, William G. Wierda, Iris Isufi, Joseph Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori A. Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Yao Wang, Michael Wang, Catriona Jamieson, Thomas J. Kipps
Journal: Blood
Blood (2021) 138 (Supplement 1): 3534.
https://doi.org/10.1182/blood-2021-148779
Published: 2021
Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Hun Ju Lee, MD, Michael Y. Choi, MD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Jacqueline C. Barrientos, MD, Nicole Lamanna, MD, Alec Goldenberg, MD, Iris Isufi, MD, Joseph Tuscano, MD, Suki Subbiah, MD, Jean L. Koff, MD, Lori A. Leslie, MD, Gina G Chung, MD, Elizabeth K Weihe, MD, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Frank J Hsu, MD, Michael Wang, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141917
Published: 2020
Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1755.
https://doi.org/10.1182/blood-2019-131498
Published: 2019
Journal Articles

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab

Julie A. Bowles, Siao-Yi Wang, Brian K. Link, Barrett Allan, Gregory Beuerlein, Mary-Ann Campbell, David Marquis, Brian Ondek, James E. Wooldridge, Brian J. Smith, James B. Breitmeyer, George J. Weiner
Journal: Blood
Blood (2006) 108 (8): 2648–2654.
https://doi.org/10.1182/blood-2006-04-020057
Published: 2006
Journal Articles

Anti-CD20 Monoclonal Antibody (mAb) with Enhanced Affinity for CD16 Activates NK Cells at Lower Concentrations and More Effectively Than Rituximab ®.

George J. Weiner, MD, Julie A. Bowles, BS, Brian K. Link, MD, Mary A. Campbell, PhD, James E. Wooldridge, MD, James B. Breitmeyer, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 348.
https://doi.org/10.1182/blood.V106.11.348.348
Published: 2005